{"type":"rich","version":"1.0","title":"The BioPharm Brief: Designations, Decisions, and Data","description":"Today's episode explores how FDA expedited pathways continue to shape advanced therapy development, from new RMAT designations for cell and gene therapies to an advisory committee review that underscores the agency's evolving expectations for clinical evidence.","author_name":"The BioPharm Brief","author_url":"https://audioboom.com/channels/5167274-the-biopharm-brief","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43766076/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":""}